Literature DB >> 26159609

Impact of time to return of spontaneous circulation on neuroprotective effect of targeted temperature management at 33 or 36 degrees in comatose survivors of out-of hospital cardiac arrest.

Jesper Kjaergaard1, Niklas Nielsen2, Matilde Winther-Jensen3, Michael Wanscher4, Tommaso Pellis5, Michael Kuiper6, Jakob Hartvig Thomsen3, Jørn Wetterslev7, Tobias Cronberg8, John Bro-Jeppesen3, David Erlinge9, Hans Friberg10, Helle Søholm3, Yvan Gasche11, Janneke Horn12, Jan Hovdenes13, Pascal Stammet14, Matthew P Wise15, Anders Åneman16, Christian Hassager3.   

Abstract

AIM: Time to Return of Spontaneous Circulation (ROSC) has a plausible relation to severity of hypoxic injury before and during resuscitation in Out-of-Hospital Cardiac Arrest (OHCA), and has consistently been associated with adverse outcome. The effect of Targeted Temperature Management (TTM) may not be similar over the full spectrum of time to ROSC. This study investigated the possible beneficial effect of targeting 33°C over 36°C on the prognostic importance of time to ROSC.
METHODS: In predefined sub-study of the TTM-trial (NEJM 2013) we investigated the relationship between time to ROSC, level of TTM and mortality and neurological outcome as assessed by the Cerebral Performance Category (CPC) scale and modified Rankin Scale (mRS) after 180 days.
RESULTS: Prolonged time to ROSC was significantly associated with increased mortality with a hazard ratio (HR) of 1.02 per minute (95% CI 1.01-1.02). Level of TTM did not modify the association of time to ROSC and mortality, pinteraction=0.85. Prolonged time to ROSC was associated with reduced odds of surviving with a favorable neurological outcome for CPC (p=0.008 for CPC 1-2) and mRS (p=0.17, mRS 0-3) with no significant interaction with level of TTM.
CONCLUSION: Time to ROSC remains a significant prognostic factor in comatose OHCA patients with regards to risk of death and risk of adverse neurological outcome. For any time to ROSC, targeting 33°C in TTM was not associated with benefit with regards to reducing mortality or risk of adverse neurological outcome compared to targeting 36°C.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26159609     DOI: 10.1016/j.resuscitation.2015.06.021

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  11 in total

Review 1.  Neurologic Recovery After Cardiac Arrest: a Multifaceted Puzzle Requiring Comprehensive Coordinated Care.

Authors:  Carolina B Maciel; Mary M Barden; David M Greer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-07

2.  Early predictors of poor outcome after out-of-hospital cardiac arrest.

Authors:  Louise Martinell; Niklas Nielsen; Johan Herlitz; Thomas Karlsson; Janneke Horn; Matt P Wise; Johan Undén; Christian Rylander
Journal:  Crit Care       Date:  2017-04-13       Impact factor: 9.097

3.  Targeted temperature management guided by the severity of hyperlactatemia for out-of-hospital cardiac arrest patients: a post hoc analysis of a nationwide, multicenter prospective registry.

Authors:  Tomoya Okazaki; Toru Hifumi; Kenya Kawakita; Yasuhiro Kuroda
Journal:  Ann Intensive Care       Date:  2019-11-19       Impact factor: 6.925

4.  Association between Cardiac Arrest Time and Favorable Neurological Outcomes in Witnessed Out-of-Hospital Cardiac Arrest Patients Treated with Targeted Temperature Management.

Authors:  Zoon Ho Lee; Yong Hwan Kim; Jun Ho Lee; Dong Woo Lee; Kyoung Yul Lee; Seong Youn Hwang
Journal:  J Korean Med Sci       Date:  2020-04-27       Impact factor: 2.153

Review 5.  Differential Effectiveness of Hypothermic Targeted Temperature Management According to the Severity of Post-Cardiac Arrest Syndrome.

Authors:  Kazuya Kikutani; Mitsuaki Nishikimi; Tatsutoshi Shimatani; Michihito Kyo; Shinichiro Ohshimo; Nobuaki Shime
Journal:  J Clin Med       Date:  2021-11-30       Impact factor: 4.241

6.  Time-differentiated target temperature management after out-of-hospital cardiac arrest: a multicentre, randomised, parallel-group, assessor-blinded clinical trial (the TTH48 trial): study protocol for a randomised controlled trial.

Authors:  Hans Kirkegaard; Bodil S Rasmussen; Inge de Haas; Jørgen Feldbæk Nielsen; Susanne Ilkjær; Anne Kaltoft; Anni Nørregaard Jeppesen; Anders Grejs; Christophe Henri Valdemar Duez; Alf Inge Larsen; Ville Pettilä; Valdo Toome; Urmet Arus; Fabio Silvio Taccone; Christian Storm; Markus B Skrifvars; Eldar Søreide
Journal:  Trials       Date:  2016-05-04       Impact factor: 2.279

7.  Different Respiratory Rates during Resuscitation in a Pediatric Animal Model of Asphyxial Cardiac Arrest.

Authors:  Jorge López; Sarah N Fernández; Rafael González; María J Solana; Javier Urbano; Jesús López-Herce
Journal:  PLoS One       Date:  2016-09-12       Impact factor: 3.240

8.  Artificial neural networks improve early outcome prediction and risk classification in out-of-hospital cardiac arrest patients admitted to intensive care.

Authors:  Jesper Johnsson; Ola Björnsson; Peder Andersson; Andreas Jakobsson; Tobias Cronberg; Gisela Lilja; Hans Friberg; Christian Hassager; Jesper Kjaergard; Matt Wise; Niklas Nielsen; Attila Frigyesi
Journal:  Crit Care       Date:  2020-07-30       Impact factor: 9.097

9.  Temporal trends in the use of targeted temperature management after cardiac arrest and association with outcome: insights from the Paris Sudden Death Expertise Centre.

Authors:  Jean-Baptiste Lascarrou; Florence Dumas; Wulfran Bougouin; Richard Chocron; Frankie Beganton; Stephane Legriel; Nadia Aissaoui; Nicolas Deye; Lionel Lamhaut; Daniel Jost; Antoine Vieillard-Baron; Eloi Marijon; Xavier Jouven; Alain Cariou
Journal:  Crit Care       Date:  2019-12-03       Impact factor: 9.097

10.  Comparison of in-hospital and out-of-hospital cardiac arrest patients receiving targeted temperature management: A matched case-control study.

Authors:  Chung-Ting Chen; Cheng-Han Chen; Tzu-Yin Chen; David Hung-Tsang Yen; Chorng-Kuang How; Peter Chuanyi Hou
Journal:  J Chin Med Assoc       Date:  2020-09       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.